U.S. markets close in 4 hours 6 minutes

GSK plc (GSK.BA)

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
3,210.00+5.00 (+0.16%)
As of 12:38PM ART. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3,205.00
Bid3,205.50 x N/A
Ask3,217.00 x N/A
Day's Range3,210.00 - 3,250.00
52 Week Range2,171.50 - 4,028.75
Avg. Volume732
Market Cap26.285T
Beta (5Y Monthly)N/A
PE Ratio (TTM)25.54
EPS (TTM)125.67
Earnings DateN/A
Forward Dividend & Yield63.32 (1.95%)
Ex-Dividend DateNov 17, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GSK.BA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Insider Monkey

      GSK plc (NYSE:GSK) Q4 2022 Earnings Call Transcript

      GSK plc (NYSE:GSK) Q4 2022 Earnings Call Transcript February 1, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the analyst call of GSK Fourth Quarter 2020 Results. I will now hand you over to Nick Stone, Head of Global Investor Relations, who will introduce today’s session. Nick Stone: Thank you, operator. Hello, everyone. […]

    • Zacks

      GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

      GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

    • Reuters

      UPDATE 2-U.S. FDA approves GSK's anemia drug for patients on dialysis

      The U.S. Food and Drug Administration (FDA) on Wednesday approved GSK Plc's drug as the first oral treatment for anemia caused by chronic kidney disease in adults who have been on dialysis for at least four months. The drug Jesduvroq comes with the boxed warning for increased thrombotic vascular events, including death, heart attack, stroke, and blood clots in the lungs, legs, or dialysis access site. The warnings and precautions also include a risk of hospitalization for heart failure, worsening increase of blood pressure, stomach erosions, and gastrointestinal bleeding.